Logo image of ALERS.PA

EUROBIO-SCIENTIFIC (ALERS.PA) Stock Fundamental Analysis

EPA:ALERS - Euronext Paris - Matif - FR0013240934 - Common Stock - Currency: EUR

25.35  0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ALERS. ALERS was compared to 72 industry peers in the Biotechnology industry. ALERS gets an excellent profitability rating and is at the same time showing great financial health properties. ALERS is not valued too expensively and it also shows a decent growth rate. With these ratings, ALERS could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year ALERS was profitable.
ALERS had a positive operating cash flow in the past year.
Each year in the past 5 years ALERS has been profitable.
In the past 5 years ALERS always reported a positive cash flow from operatings.
ALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M

1.2 Ratios

ALERS's Return On Assets of 2.12% is fine compared to the rest of the industry. ALERS outperforms 76.39% of its industry peers.
With a decent Return On Equity value of 3.72%, ALERS is doing good in the industry, outperforming 79.17% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.16%, ALERS belongs to the top of the industry, outperforming 81.94% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ALERS is above the industry average of 11.80%.
The last Return On Invested Capital (4.16%) for ALERS is well below the 3 year average (14.53%), which needs to be investigated, but indicates that ALERS had better years and this may not be a problem.
Industry RankSector Rank
ROA 2.12%
ROE 3.72%
ROIC 4.16%
ROA(3y)12.64%
ROA(5y)16.89%
ROE(3y)18.31%
ROE(5y)26.49%
ROIC(3y)14.53%
ROIC(5y)18.91%
ALERS.PA Yearly ROA, ROE, ROICALERS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

1.3 Margins

Looking at the Profit Margin, with a value of 4.61%, ALERS is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
ALERS's Profit Margin has declined in the last couple of years.
ALERS's Operating Margin of 9.75% is amongst the best of the industry. ALERS outperforms 83.33% of its industry peers.
In the last couple of years the Operating Margin of ALERS has declined.
ALERS has a better Gross Margin (46.75%) than 61.11% of its industry peers.
ALERS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9.75%
PM (TTM) 4.61%
GM 46.75%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3Y-54.28%
PM growth 5YN/A
GM growth 3Y-6.94%
GM growth 5Y5.2%
ALERS.PA Yearly Profit, Operating, Gross MarginsALERS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

7

2. Health

2.1 Basic Checks

ALERS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, ALERS has less shares outstanding
Compared to 5 years ago, ALERS has more shares outstanding
The debt/assets ratio for ALERS has been reduced compared to a year ago.
ALERS.PA Yearly Shares OutstandingALERS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALERS.PA Yearly Total Debt VS Total AssetsALERS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.81 indicates that ALERS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALERS has a Altman-Z score of 2.81. This is in the better half of the industry: ALERS outperforms 76.39% of its industry peers.
The Debt to FCF ratio of ALERS is 4.71, which is a neutral value as it means it would take ALERS, 4.71 years of fcf income to pay off all of its debts.
ALERS's Debt to FCF ratio of 4.71 is amongst the best of the industry. ALERS outperforms 84.72% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that ALERS is not too dependend on debt financing.
ALERS has a Debt to Equity ratio (0.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 4.71
Altman-Z 2.81
ROIC/WACC0.54
WACC7.69%
ALERS.PA Yearly LT Debt VS Equity VS FCFALERS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

ALERS has a Current Ratio of 2.69. This indicates that ALERS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.69, ALERS perfoms like the industry average, outperforming 56.94% of the companies in the same industry.
A Quick Ratio of 2.26 indicates that ALERS has no problem at all paying its short term obligations.
ALERS has a Quick ratio (2.26) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.26
ALERS.PA Yearly Current Assets VS Current LiabilitesALERS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

ALERS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.70%.
The earnings per share for ALERS have been decreasing by -59.58% on average. This is quite bad
ALERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.58%.
ALERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.80% yearly.
EPS 1Y (TTM)-15.7%
EPS 3Y-59.58%
EPS 5YN/A
EPS Q2Q%105.99%
Revenue 1Y (TTM)12.58%
Revenue growth 3Y-11.7%
Revenue growth 5Y20.8%
Sales Q2Q%23.86%

3.2 Future

ALERS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.42% yearly.
Based on estimates for the next years, ALERS will show a small growth in Revenue. The Revenue will grow by 6.29% on average per year.
EPS Next Y-2.22%
EPS Next 2Y11.06%
EPS Next 3Y16.42%
EPS Next 5YN/A
Revenue Next Year6.07%
Revenue Next 2Y6.69%
Revenue Next 3Y6.29%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALERS.PA Yearly Revenue VS EstimatesALERS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALERS.PA Yearly EPS VS EstimatesALERS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

ALERS is valuated quite expensively with a Price/Earnings ratio of 39.61.
80.56% of the companies in the same industry are more expensive than ALERS, based on the Price/Earnings ratio.
ALERS is valuated rather expensively when we compare the Price/Earnings ratio to 29.35, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 22.17, the valuation of ALERS can be described as rather expensive.
Based on the Price/Forward Earnings ratio, ALERS is valued cheaply inside the industry as 83.33% of the companies are valued more expensively.
ALERS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.10.
Industry RankSector Rank
PE 39.61
Fwd PE 22.17
ALERS.PA Price Earnings VS Forward Price EarningsALERS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

87.50% of the companies in the same industry are more expensive than ALERS, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ALERS is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.02
EV/EBITDA 9.22
ALERS.PA Per share dataALERS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The decent profitability rating of ALERS may justify a higher PE ratio.
ALERS's earnings are expected to grow with 16.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.06%
EPS Next 3Y16.42%

More info and screens

0

5. Dividend

5.1 Amount

ALERS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROBIO-SCIENTIFIC

EPA:ALERS (3/7/2025, 7:00:00 PM)

25.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-01 2024-10-01
Earnings (Next)04-08 2025-04-08/amc
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap259.84M
Analysts84.44
Price Target30.6 (20.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 39.61
Fwd PE 22.17
P/S 1.8
P/FCF 13.02
P/OCF 11.26
P/B 1.45
P/tB 9.19
EV/EBITDA 9.22
EPS(TTM)0.64
EY2.52%
EPS(NY)1.14
Fwd EY4.51%
FCF(TTM)1.95
FCFY7.68%
OCF(TTM)2.25
OCFY8.88%
SpS14.06
BVpS17.43
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.12%
ROE 3.72%
ROCE 5.42%
ROIC 4.16%
ROICexc 6.24%
ROICexgc 48.46%
OM 9.75%
PM (TTM) 4.61%
GM 46.75%
FCFM 13.85%
ROA(3y)12.64%
ROA(5y)16.89%
ROE(3y)18.31%
ROE(5y)26.49%
ROIC(3y)14.53%
ROIC(5y)18.91%
ROICexc(3y)31.05%
ROICexc(5y)40.03%
ROICexgc(3y)76.58%
ROICexgc(5y)85.22%
ROCE(3y)19.05%
ROCE(5y)24.73%
ROICexcg growth 3Y-35.22%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.78%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3Y-54.28%
PM growth 5YN/A
GM growth 3Y-6.94%
GM growth 5Y5.2%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 4.71
Debt/EBITDA 2.71
Cap/Depr 20.88%
Cap/Sales 2.16%
Interest Coverage 250
Cash Conversion 79.6%
Profit Quality 300.41%
Current Ratio 2.69
Quick Ratio 2.26
Altman-Z 2.81
F-Score7
WACC7.69%
ROIC/WACC0.54
Cap/Depr(3y)28.59%
Cap/Depr(5y)28.36%
Cap/Sales(3y)1.99%
Cap/Sales(5y)1.98%
Profit Quality(3y)245.65%
Profit Quality(5y)183.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.7%
EPS 3Y-59.58%
EPS 5YN/A
EPS Q2Q%105.99%
EPS Next Y-2.22%
EPS Next 2Y11.06%
EPS Next 3Y16.42%
EPS Next 5YN/A
Revenue 1Y (TTM)12.58%
Revenue growth 3Y-11.7%
Revenue growth 5Y20.8%
Sales Q2Q%23.86%
Revenue Next Year6.07%
Revenue Next 2Y6.69%
Revenue Next 3Y6.29%
Revenue Next 5YN/A
EBIT growth 1Y-14.9%
EBIT growth 3Y-43.64%
EBIT growth 5YN/A
EBIT Next Year19.3%
EBIT Next 3Y15.47%
EBIT Next 5YN/A
FCF growth 1Y-66.71%
FCF growth 3Y-24.43%
FCF growth 5YN/A
OCF growth 1Y-62.47%
OCF growth 3Y-21.31%
OCF growth 5YN/A